Quantcast
Last updated on April 19, 2014 at 13:20 EDT

Latest European Society of Cardiology Stories

2011-09-23 12:03:51

The European Chronic Disease Alliance welcomes the UN High Level Meeting on Non-Communicable Diseases to address the world's biggest killers The European Chronic Disease Alliance (ECDA) welcomes the UN High Level Meeting on Non Communicable Diseases (NCDs) to address the world biggest killers. "It is a memorable day in the history of public health. Discussing non communicable diseases at the UN table gives a strong sense of the burden it represents to human kind and the recognition that...

2011-09-01 06:00:00

TSX Exchange Symbol: RVX CALGARY, Sept. 1, 2011 /PRNewswire/ - Resverlogix Corp. ("Resverlogix") (TSX: RVX) announced today that two abstracts on the analysis of the ASSERT trial were presented at the European Society of Cardiology (ESC) Congress 2011 in Paris, France. The abstracts were co-authored by Resverlogix Senior Scientists and Clinical Steering Committee members: S.J. Nicholls, A. Gordon, J. Johansson, C.M. Ballantyne, J.J.P. Kastelein, N.C.W. Wong, M. Borgman, K. Wolski,...

2011-08-30 18:25:48

Outcomes in GRAVITAS trial Compared to patients who had persistently high platelet reactivity, those who achieved low platelet reactivity, according to the VerifyNow P2Y12 Test, had a reduced incidence of cardiovascular death, heart attack and stent thrombosis, as indicated by a clinical trial presented today at the ESC Congress 2011. These findings were part of a secondary analysis of the Gauging Responsiveness with A VerifyNow P2Y12 Assay- Impact on Thrombosis and Safety (GRAVITAS)...

2011-08-30 15:56:14

A report from the nationwide complete Swedish Coronary Angiography and Angioplasty Registry (SCAAR) Results from the SCAAR study, presented at the ESC Congress 2011 today, showed that Percutaneous Coronary Intervention (PCI) with "new generation" Drug Eluting Stents, was associated with a 38% lower risk of clinically meaningful restenosis and a 50% lower risk of stent thrombosis compared to old generation DES. Although many trials and studies support the overall early and mid-term...

2011-08-30 15:04:20

Safety and tolerability of the oral Xa inhibitor darexaban for secondary prevention after acute coronary syndromes A phase II dose-finding study has found that the new oral Factor Xa inhibitor darexaban was associated with a two to four-fold increase in bleeding when added to dual antiplatelet therapy in patients following an acute coronary syndrome. Professor Gabriel Steg from the Hôpital Bichat in Paris, presenting results from the RUBY-1 trial in a Hot Line session of...

2011-08-30 11:42:43

Many patients are looking for a drug-free lifestyle Results presented today from the Atrial Fibrillation Ablation Pilot Study show that almost 40% of patients undergoing a catheter ablation for atrial fibrillation have no underlying disease associated with the arrhythmia, and precipitating factors are rare. The survey, which is a pilot survey from the ESC's EurObservational registry program, also confirmed that symptoms are present in 86% of patients but vary considerably; symptoms include...

2011-08-30 11:40:36

but continuing poor outcomes in acute conditions With the increased prevalence of chronic heart failure (HF), there is a concomitant increase in the number of related hospitalizations; as chronic HF progresses, the risk of acute exacerbation increases. Registries and surveys of HF have been generally conducted in patients with either chronic or acute conditions, but a description of the whole clinical history of patients with HF, including the acute episodes, consequent changes in...

2011-08-30 11:29:58

(Less that 20 percent) logistic Euroscore: results of a prospective single center registry Results from a study presented today at the ESC Congress 2011, show that TAVI implantation in low risk patients, met with 100% procedural success (versus 95.3% in the high Euroscore group (p=0.1). "The most interesting point to observe is the absence of death at one month in the low Euroscore group, versus a mortality rate of 11.1% in the high Euroscore group (>20%), (p < 0.04) and this...

Vigorous Exercise Recommended For A Longer Life
2011-08-30 07:50:18

  New Danish research confirms previous evidence that relative intensity is more important in cycling than the duration when it comes to protection of cardiovascular disease. The study, presented at the European Society of Cardiology (ESC) Congress 2011 on Monday, showed that men who cycle with fast intensity survived 5.3 years longer than men who cycled with slow intensity. And in men who cycled with moderate intensity survived 2.9 years longer. For women, the figures were 3.9 and...

2011-08-29 21:04:42

"A multidisciplinary educational programme in cardiovascular prevention directed to children of school age can reduce their parents' cardiovascular risk. Cardiovascular prevention could have more success focusing on children first, inducing healthier lifestyle habits in the whole family, "said investigator Luciana Fornari, from the University of Sao Paulo, Brazil. The inspiration for this study, presented today at the ESC Congress 2011 in Paris, came with her motherhood, and the perception...